By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Pharmacyclics, Inc. 

995 East Arques Avenue

Sunnyvale  California  94086  U.S.A.
Phone: 408-774-0330 Fax: 408-774-0340


SEARCH JOBS








Company News
Pharmacyclics, Inc. (PCYC) Announces Preliminary 2014 U.S. Net Product Revenue Results And 2015 U.S. Net Product Revenue Outlook 1/13/2015 9:50:40 AM
Pharmacyclics, Inc. (PCYC) Release: IMBRUVICA┬« (ibrutinib) Data Demonstrates Efficacy In Previously Untreated And Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia Patients 1/5/2015 7:29:12 AM
Pharmacyclics, Inc. (PCYC) Announces Update On IMBRUVICA┬« (Ibrutinib) Waldenstrom's Macroglobulinemia (WM) Submission 12/22/2014 8:19:16 AM
Pharmacyclics, Inc. (PCYC) Named 2014 Outstanding Company By BayBio (Bay Area Bioscience Association) 12/12/2014 8:23:38 AM
Pharmacyclics, Inc. (PCYC) Release: Longer Follow-Up IMBRUVICA (ibrutinib) Treatment Demonstrates Sustained Efficacy In Patients With Difficult-To-Treat Chronic Lymphocytic Leukemia (CLL) 12/9/2014 8:46:15 AM
Pharmacyclics, Inc. (PCYC) Release: IMBRUVICA (ibrutinib) Data Demonstrates Safety And Durability Of Response At Two-Year Follow-Up In Mantle Cell Lymphoma 12/9/2014 7:15:39 AM
Pharmacyclics, Inc. (PCYC) Release: Longer Follow-Up IMBRUVICA (ibrutinib) Treatment Demonstrates Sustained Efficacy In Patients With Difficult-To-Treat Chronic Lymphocytic Leukemia (CLL) 12/9/2014 7:12:54 AM
Pharmacyclics, Inc. (PCYC) Release: IMBRUVICA (ibrutinib) In Combination With Rituximab Data Shows Positive Benefit-Risk Profile In Hematologic Malignancy 12/9/2014 7:10:37 AM
Pharmacyclics, Inc. (PCYC) Announces Launch of informCLL Registry For Chronic Lymphocytic Leukemia (CLL) Patients 12/8/2014 9:29:57 AM
Pharmacyclics, Inc. (PCYC) Release: IMBRUVICA (ibrutinib) Data Suggests Promise In Multiple Myeloma 12/8/2014 7:38:13 AM
12345678910...
//-->